MA30888B1 - Compositions et procedes de modulation de recepteurs de c-kit et de facteur de croissance derive de plaquettes (pdgfr) - Google Patents

Compositions et procedes de modulation de recepteurs de c-kit et de facteur de croissance derive de plaquettes (pdgfr)

Info

Publication number
MA30888B1
MA30888B1 MA31869A MA31869A MA30888B1 MA 30888 B1 MA30888 B1 MA 30888B1 MA 31869 A MA31869 A MA 31869A MA 31869 A MA31869 A MA 31869A MA 30888 B1 MA30888 B1 MA 30888B1
Authority
MA
Morocco
Prior art keywords
pdgfr
methods
raf
compounds
modulating
Prior art date
Application number
MA31869A
Other languages
English (en)
Inventor
Donatella Chianelli
Christopher Cow
Yun He
Songchun Jiang
Xiaolin Li
Xiaodong Liu
Jon Loren
Valentina Molteni
Juliet Nabakka
Pingda Ren
Taebo Sim
Xiaodong Wang
Shuli You
Zuosheng Liu
Original Assignee
Irm Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39027274&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA30888(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Irm Llc filed Critical Irm Llc
Publication of MA30888B1 publication Critical patent/MA30888B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Molecular Biology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychology (AREA)
  • Transplantation (AREA)
  • Child & Adolescent Psychology (AREA)

Abstract

LA PRÉSENTE INVENTION CONCERNE DES COMPOSÉS ET DES COMPOSITIONS PHARMACEUTIQUES UTILES EN TANT QU'INHIBITEURS DE LA PROTÉINE KINASE, AINSI QUE DES PROCÉDÉS D'UTILISATION DE TELS COMPOSÉS POUR TRAITER, AMÉLIORER OU PRÉVENIR UNE CONDITION ASSOCIÉE À UNE ACTIVITÉ ANORMALE OU DÉRÉGLÉE DES KINASES. SELON CERTAINS MODES DE RÉALISATION, L'INVENTION CONCERNE DES PROCÉDÉS D'UTILISATION DE TELS COMPOSÉS POUR TRAITER, AMÉLIORER OU PRÉVENIR DES MALADIES OU TROUBLES IMPLIQUANT L'ACTIVATION ANORMALE DE C-KIT, PDGFR , PDGFR , CSF1R, ABL, BCR-ABL, CSK, JNK1, JNK2, P38, P70S6K, TGF , SRC, EGFR, TRKB, FGFR3, FLT3, FES, LCK, SYK, RAF, MKK4, MKK6, SAPK2, BRK, KDR, C-RAF OU B-RAF KINASE, OU DES FORMES MUTANTES DE CEUX-CI
MA31869A 2006-10-20 2009-05-13 Compositions et procedes de modulation de recepteurs de c-kit et de facteur de croissance derive de plaquettes (pdgfr) MA30888B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US86243006P 2006-10-20 2006-10-20

Publications (1)

Publication Number Publication Date
MA30888B1 true MA30888B1 (fr) 2009-11-02

Family

ID=39027274

Family Applications (1)

Application Number Title Priority Date Filing Date
MA31869A MA30888B1 (fr) 2006-10-20 2009-05-13 Compositions et procedes de modulation de recepteurs de c-kit et de facteur de croissance derive de plaquettes (pdgfr)

Country Status (25)

Country Link
US (2) US7678792B2 (fr)
EP (1) EP2076513A1 (fr)
JP (1) JP2010506948A (fr)
KR (1) KR101079520B1 (fr)
CN (1) CN101528744A (fr)
AR (1) AR063343A1 (fr)
AU (1) AU2007309279B2 (fr)
BR (1) BRPI0718162A2 (fr)
CA (1) CA2667010A1 (fr)
CL (1) CL2007003005A1 (fr)
CO (1) CO6170361A2 (fr)
CR (1) CR10717A (fr)
EA (1) EA200900573A1 (fr)
EC (1) ECSP099353A (fr)
IL (1) IL197875A0 (fr)
MA (1) MA30888B1 (fr)
MX (1) MX2009004141A (fr)
NI (1) NI200900061A (fr)
NO (1) NO20091949L (fr)
PE (1) PE20081262A1 (fr)
SM (1) SMP200900027B (fr)
TN (1) TN2009000145A1 (fr)
TW (1) TW200825081A (fr)
WO (1) WO2008051757A1 (fr)
ZA (1) ZA200902711B (fr)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7794965B2 (en) 2002-03-13 2010-09-14 Signum Biosciences, Inc. Method of identifying modulators of PP2A methylase
EP1843734A4 (fr) 2005-02-03 2008-09-10 Signum Biosciences Inc Compositions et procedes pour l'amelioration de la fonction cognitive
US7923041B2 (en) 2005-02-03 2011-04-12 Signum Biosciences, Inc. Compositions and methods for enhancing cognitive function
US7897762B2 (en) 2006-09-14 2011-03-01 Deciphera Pharmaceuticals, Llc Kinase inhibitors useful for the treatment of proliferative diseases
US8188113B2 (en) * 2006-09-14 2012-05-29 Deciphera Pharmaceuticals, Inc. Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
AR063621A1 (es) 2006-11-09 2009-02-04 Alcon Res Ltd Matriz polimerica insoluble en agua para la administracion de farmacos
TWI498115B (zh) * 2007-12-27 2015-09-01 Daiichi Sankyo Co Ltd 咪唑羰基化合物
CA2714700C (fr) * 2008-02-22 2013-07-30 Irm Llc Composes et compositions heterocycliques comme inhibiteurs de c-kit et pdgfr kinase
CN102014897B (zh) 2008-04-21 2015-08-05 西格纳姆生物科学公司 化合物、组合物和其制备方法
FR2930552B1 (fr) * 2008-04-24 2012-10-12 Centre Nat Rech Scient N-acylthiourees et n-acylurees inhibiteurs de la voie de signalisation des proteines hedgehog
CN102089278A (zh) * 2008-06-11 2011-06-08 Irm责任有限公司 用于治疗疟疾的化合物和组合物
WO2010017331A1 (fr) * 2008-08-05 2010-02-11 George Mason Intellectual Properties, Inc. Altérations de voie de signalisation et élévations de médicament cible dans le cancer colorectal métastasique métachrone primaire comparé à une maladie non métastasique
MX2011004535A (es) * 2008-10-29 2011-11-18 Deciphera Pharmaceuticals Llc Ciclopropanamidas y analogos que exhiben actividades anti-cancer y anti-proliferativas.
TW201034675A (en) * 2008-12-18 2010-10-01 Sanofi Aventis Method for treating macular degeneration
US8674095B2 (en) 2008-12-19 2014-03-18 Afraxis Holdings, Inc. Compounds for treating neuropsychiatric conditions
KR20110116160A (ko) * 2009-02-13 2011-10-25 포비어 파마수티칼스 카이네이스 저해제로서의 〔1,2,4〕트리아졸로〔1,5-ａ〕피리딘
AU2010303218A1 (en) 2009-10-09 2012-05-10 Afraxis Holdings, Inc. 8-ethyl-6-(aryl)pyrido[2,3-d]pyrimidin-7(8H)-ones for the treatment of CNS disorders
EP2528915B1 (fr) 2010-01-29 2015-10-28 Boehringer Ingelheim International GmbH Naphtyridines substituées et leur utilisation comme inhibiteurs de syk kinase
EP2531498B1 (fr) 2010-02-05 2016-07-13 Novartis AG Composés et compositions comme inhibiteurs de protéine-kinases
DK2668210T3 (da) * 2011-01-26 2020-08-24 Celldex Therapeutics Inc Anti-kit antistoffer og anvendelser deraf
PL2701510T3 (pl) * 2011-04-25 2017-07-31 Usher Iii Initiative Inc Pirazolopirydazyny oraz sposoby leczenia zwyrodnieniowych chorób siatkówki i utraty słuchu związanych z zespołem ushera
AU2012288969B2 (en) * 2011-07-26 2017-02-23 Boehringer Ingelheim International Gmbh Substituted quinolines and their use as medicaments
WO2013049407A2 (fr) * 2011-09-30 2013-04-04 Kineta, Inc Composés anti-viraux
SI2861579T1 (en) 2012-05-15 2018-05-31 Novartis Ag Benzamide derivatives for inhibiting the activity of ABL1, ABL2 and BCR-ABL1
MX357305B (es) 2012-05-15 2018-07-04 Novartis Ag Compuestos y composiciones para inhibir la actividad de abl-1, abl-2, y bcr-abl1.
EA201492005A1 (ru) 2012-05-15 2015-04-30 Новартис Аг Бензамидные производные для ингибирования активности abl1, abl2 и bcr-abl1
CN104302634B (zh) 2012-05-15 2017-02-08 诺华股份有限公司 用于抑制abl1、abl2和bcr‑abl1的活性的苯甲酰胺衍生物
US8461179B1 (en) 2012-06-07 2013-06-11 Deciphera Pharmaceuticals, Llc Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
CN104902895B (zh) * 2012-06-07 2019-03-29 德西费拉制药有限责任公司 可用作用于治疗增生性疾病的激酶抑制剂的二氢萘啶和相关化合物
CN116574185A (zh) 2012-07-25 2023-08-11 塞尔德克斯医疗公司 抗kit抗体及其用途
US9227976B2 (en) 2012-10-25 2016-01-05 Usher Iii Initiative, Inc. Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome
US20160151335A1 (en) * 2013-06-26 2016-06-02 Proteostasis Therapeutics, Inc. Methods of modulating cftr activity
GB201401886D0 (en) 2014-02-04 2014-03-19 Lytix Biopharma As Neurodegenerative therapies
WO2015138934A1 (fr) 2014-03-13 2015-09-17 Proteostasis Therapeutics, Inc. Composés, compositions et procédés pour augmenter l'activité cftr
US9790219B2 (en) 2014-03-13 2017-10-17 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods for increasing CFTR activity
CN113908269A (zh) 2014-05-23 2022-01-11 塞尔德克斯医疗公司 嗜酸性粒细胞或肥大细胞相关病症的治疗
EP3157917B1 (fr) 2014-06-19 2020-03-18 Proteostasis Therapeutics, Inc. Composés, compositions et procédés pour augmenter l'activité du cftr
CN105085489B (zh) 2014-11-05 2019-03-01 益方生物科技（上海）有限公司 嘧啶或吡啶类化合物、其制备方法和医药用途
WO2016105468A1 (fr) 2014-12-23 2016-06-30 Proteostasis Therapeutics, Inc. Dérivés de 3-hétéroarylisoxazol-5-amide carboxylique utiles dans le traitement, entre autres, d'une fibrose kystique
MA41253A (fr) 2014-12-23 2017-10-31 Proteostasis Therapeutics Inc Composés, compositions et procédés pour augmenter l'activité du cftr
WO2016105477A1 (fr) 2014-12-23 2016-06-30 Proteostasis Therapeutics, Inc Dérivés d'amides 5-phényl- ou 5-hétéroarylthiazol-2-carboxyliques servant au traitement, entre autres, de la fibrose cystique
WO2016105484A1 (fr) 2014-12-23 2016-06-30 Proteostasis Therapeutics, Inc. Dérivés d'amide 5-(hétéro)arylpyrazol-3-carboxylique ou d'amide 1-(hétéro)aryltriazol-4-carboxylique utiles pour le traitement, entre autres, de la fibrose kystique
AU2016297886B2 (en) 2015-07-24 2020-12-10 Proteostasis Therapeutics, Inc. Compounds, compositions and methods of increasing CFTR activity
CN105664178B (zh) * 2015-09-24 2019-08-20 洪健 Syk作为肝纤维化/硬化治疗靶点的应用
CA3000483C (fr) 2015-10-06 2024-02-13 Proteostasis Therapeutics, Inc. Composes, compositions et methodes permettant de moduler le cftr
CN107286077B (zh) * 2016-04-01 2021-04-02 合肥中科普瑞昇生物医药科技有限公司 一种选择性的c-kit激酶抑制剂
EP3440057B1 (fr) 2016-04-07 2021-09-22 Proteostasis Therapeutics, Inc. Analogues du ivacaftor conentant des atomes de silicium
MA45397A (fr) 2016-06-21 2019-04-24 Proteostasis Therapeutics Inc Composés, compositions et procédés pour augmenter l'activité du cftr
JP7096817B2 (ja) * 2016-11-04 2022-07-06 オークランド ユニサービシーズ リミティド 三環式複素環式誘導体及びその使用
MA49014A (fr) 2017-03-21 2020-02-05 Arbutus Biopharma Corp Dihydroindène-4-carboxamides substitués, leurs analogues et procédés d'utilisation correspondant
WO2018209354A1 (fr) 2017-05-12 2018-11-15 Enanta Pharmaceuticals, Inc. Inhibiteurs de kinases de régulation du signal d'apoptose 1 et leurs procédés d'utilisation
CA3065365A1 (fr) * 2017-05-30 2018-12-06 Daniel L. Flynn Utilisation de 1-[4-bromo-5-[1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridine-3-yl]-2-fluorophenyl]-3-phenyluree et de ses analogues pour le traitement de cancers assoc ies a des anomalies genetiques au niveau du recepteur alpha du facteur de croissance derive des plaquettes
WO2019056990A1 (fr) * 2017-09-20 2019-03-28 浙江海正药业股份有限公司 Dérivé de 1,2-dihydro-1,6-naphtyridine, son procédé de préparation et son application en médecine
KR20200094734A (ko) 2017-09-22 2020-08-07 주빌런트 에피파드 엘엘씨 Pad 억제제로서의 헤테로사이클릭 화합물
DK3697785T3 (da) 2017-10-18 2023-04-03 Jubilant Epipad LLC Imidazo-pyridine forbindelser som pad-inhibitorer
AU2018362046B2 (en) 2017-11-06 2023-04-13 Jubilant Prodel LLC Pyrimidine derivatives as inhibitors of PD1/PD-L1 activation
CA3083374A1 (fr) 2017-11-24 2019-05-31 Jubilant Episcribe Llc Composes heterocycliques utilises en tant qu'inhibiteurs de prmt5
CN111818915B (zh) 2018-01-31 2024-05-24 德西费拉制药有限责任公司 治疗胃肠道间质瘤的组合疗法
AU2019234185A1 (en) * 2018-03-13 2020-10-01 Jubilant Prodel LLC. Bicyclic compounds as inhibitors of PD1/PD-L1 interaction/activation
AU2019262016A1 (en) 2018-05-02 2020-11-19 Enanta Pharmaceuticals, Inc. Tetrazole containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
WO2020041417A1 (fr) * 2018-08-22 2020-02-27 Enanta Pharmaceuticals, Inc. Inhibiteurs de la kinase 1 régulant le signal d'apoptose contenant un cycloalkyle et leurs procédés d'utilisation
MX2020013757A (es) * 2018-09-14 2021-03-02 Abbisko Therapeutics Co Ltd Inhibidor del fgfr, metodo de preparacion y aplicacion del mismo.
US11345699B2 (en) 2018-11-19 2022-05-31 Enanta Pharmaceuticals, Inc. Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
WO2020198214A1 (fr) 2019-03-25 2020-10-01 Enanta Pharmaceuticals, Inc. Inhibiteurs de la kinase 1 régulant le signal d'apoptose et leurs procédés d'utilisation
AU2020329956B2 (en) 2019-08-12 2023-11-16 Deciphera Pharmaceuticals, Llc. Ripretinib for treating gastrointestinal stromal tumors
TW202122082A (zh) 2019-08-12 2021-06-16 美商迪賽孚爾製藥有限公司 治療胃腸道基質瘤方法
WO2021039791A1 (fr) * 2019-08-25 2021-03-04 国立大学法人山口大学 Composition médicinale pour la prévention ou le traitement de maladies associées à l'angiogenèse
BR112022013109A2 (pt) 2019-12-30 2022-09-06 Deciphera Pharmaceuticals Llc Formulações de inibidor de quinase amorfo e métodos de uso das mesmas
JP2023509628A (ja) 2019-12-30 2023-03-09 デシフェラ・ファーマシューティカルズ，エルエルシー １－（４－ブロモ－５－（１－エチル－７－（メチルアミノ）－２－オキソ－１，２－ジヒドロ－１，６－ナフチリジン－３－イル）－２－フルオロフェニル）－３－フェニル尿素の組成物
US20210315869A1 (en) * 2020-04-02 2021-10-14 Plexxikon Inc. Compounds and methods for csk modulation and indications therefor
IL302807A (en) 2020-11-18 2023-07-01 Deciphera Pharmaceuticals Llc GCN2 and PERK kinase inhibitors and methods of using them
CN115108997A (zh) * 2021-03-22 2022-09-27 南开大学 一类具抑菌活性的磺酰脲类化合物的合成与应用
CA3233636A1 (fr) * 2021-09-29 2023-04-06 Repare Therapeutics Inc. Composes n-([(l,3,4-thiadiazolyle) ou (thiazolyle)]-5-substitues)carboxamide (substitue) et leur utilisation pour inhiber la polymerase theta humaine
US11814384B2 (en) 2022-02-03 2023-11-14 Kinnate Biopharma Inc. Inhibtors of Raf kinases
WO2024039864A1 (fr) * 2022-08-19 2024-02-22 Purdue Research Foundation Inhibiteurs des interactions protéine-protéine
US11779572B1 (en) 2022-09-02 2023-10-10 Deciphera Pharmaceuticals, Llc Methods of treating gastrointestinal stromal tumors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002028853A1 (fr) 2000-10-02 2002-04-11 Tanabe Seiyaku Co., Ltd. Compose de benzylamine, son procede de production et produit intermediaire correspondant
AU2004279427B2 (en) 2003-10-08 2008-07-03 Irm Llc Compounds and compositions as protein kinase inhibitors
US20090312349A1 (en) * 2004-12-23 2009-12-17 Deciphera Pharmaceuticals, Llc Anti-inflammatory medicaments
EP2942349A1 (fr) * 2004-12-23 2015-11-11 Deciphera Pharmaceuticals, LLC Modulateurs d'enzymes et traitements
WO2007136465A2 (fr) 2006-05-15 2007-11-29 Irm Llc Compositions et procédés utilisés en tant qu'inhibiteurs des kinases réceptrices fgf
US8188113B2 (en) * 2006-09-14 2012-05-29 Deciphera Pharmaceuticals, Inc. Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
EP2086979B1 (fr) * 2006-11-06 2015-06-03 Tolero Pharmaceuticals, Inc. Dérivés d'imidazo[1,2-b]pyridazine et de pyrazolo[1,5-a]pyrimidine et utilisation de ceux-ci comme inhibiteurs de protéines kinases

Also Published As

Publication number Publication date
NO20091949L (no) 2009-05-19
CL2007003005A1 (es) 2008-05-23
ZA200902711B (en) 2010-05-26
BRPI0718162A2 (pt) 2013-11-26
NI200900061A (es) 2010-03-10
MX2009004141A (es) 2009-05-01
AR063343A1 (es) 2009-01-21
PE20081262A1 (es) 2008-10-29
US20100081656A1 (en) 2010-04-01
JP2010506948A (ja) 2010-03-04
KR20090054477A (ko) 2009-05-29
AU2007309279A1 (en) 2008-05-02
US8106068B2 (en) 2012-01-31
CA2667010A1 (fr) 2008-05-02
SMP200900027B (it) 2010-01-19
EA200900573A1 (ru) 2009-10-30
AU2007309279B2 (en) 2011-03-24
SMAP200900027A (it) 2009-07-14
US7678792B2 (en) 2010-03-16
CR10717A (es) 2009-07-02
KR101079520B1 (ko) 2011-11-03
ECSP099353A (es) 2009-06-30
IL197875A0 (en) 2009-12-24
EP2076513A1 (fr) 2009-07-08
WO2008051757A1 (fr) 2008-05-02
CO6170361A2 (es) 2010-06-18
US20080176846A1 (en) 2008-07-24
CN101528744A (zh) 2009-09-09
TN2009000145A1 (en) 2010-10-18
TW200825081A (en) 2008-06-16

Similar Documents

Publication Publication Date Title
MA30888B1 (fr) Compositions et procedes de modulation de recepteurs de c-kit et de facteur de croissance derive de plaquettes (pdgfr)
MA31704B1 (fr) Composés et compositions de 5-(4- (haloalkoxy) phényl) pyrimidine-2-amine utilisés comme inhibiteurs de kinases
MX2010002005A (es) Derivados de 2-heteroaril-amino-pirimidina como inhibidores de cinasa.
MA28679B1 (fr) Composes et compositions utilises comme inhibiteurs de proteines kinases
BRPI0415210A (pt) compostos e composições como inibidores de proteìna cinase
MA30772B1 (fr) Composes et compositions utilises en tant qu'inhibiteurs de proteine kinase
MA29612B1 (fr) Composes et methodes de modulation de la kinase et instructions afferentes
PL2027123T3 (pl) Związki i kompozycje jako inhibitory kinaz białkowych
MA29216B1 (fr) Composes et compositions utilises comme inhibiteurs de la proteine kinase
MX2008001605A (es) Compuestos y composiciones de tiazol-2-il amino 5-substituido como inhibidores de cinasa proteica.
BRPI0414930A (pt) compostos e composições como inibidores de proteìnas cinases
MA31153B1 (fr) Composés et méthodes pour moduler une kinase et indications associées
MX2008001969A (es) Compuestos y composiciones como inhibidores de proteina cinasa.
EA200901654A1 (ru) Ингибиторы и способы с их использованием
WO2006124731A3 (fr) Composes et compositions utilise(e)s en tant qu'inhibiteurs de proteines-kinases
MA34948B1 (fr) Composes et procedes de modulation de kinase, et leurs indications
ATE465731T1 (de) 2-aminoaryloxazol-verbindungen als tyrosinkinase- hemmer
TW200616632A (en) Compounds modulating c-kit activity and uses therefor
MA27997A1 (fr) Composes et compositions inhibiteurs de l'activite du recepteur tyrosine kinase
MX2009005428A (es) Compuestos que modulan actividad c-fms y/o c-kit y usos para ello.
EA200701804A1 (ru) Мутации рецептора эпидермального фактора роста
BRPI0414869A (pt) compostos e composições como inibidores da proteìna quinase
UA93679C2 (en) Compounds modulating c-kit and c-fms activity and uses therefor
TH98294B (th) องค์ประกอบและวิธีการสำหรับการปรับคุม C-kit รีเซปเตอร์
TH98294A (th) องค์ประกอบและวิธีการสำหรับการปรับคุม C-kit รีเซปเตอร์